The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study

This survey study assessed changes to OUD treatment, telemedicine use, and re-entry support services among carceral and CTPs participating in the National Institute on Drug Abuse (NIDA)-funded study, Long-Acting Buprenorphine vs. Naltrexone Opioid Treatments in Criminal Justice System-Involved Adults (EXIT-CJS) study. During the COVID-19 pandemic, this small sample of carceral and CTP sites innovated to…

Read More

Comparison of Long-acting Buprenorphine (Sublocade) and Naltrexone Opioid Treatments Among Justice-involved Individuals Leaving Jails (035)

This study is conducting a large multisite trial to compare the effectiveness of extended-release buprenorphine (Sublocade, XR-B) to extended-release naltrexone (XR-NTX). The trial will enroll individuals prior to release from jail and randomize to either medication option. The first dose of medication will be administered prior to release, with an additional 24 weeks of treatment received in the community.

Participating jails are located in Connecticut, Delaware, New Hampshire, New Jersey and Oregon. The study will measure retention in treatment, and opioid and other substance use outcomes between the two medication conditions, as well as a sample of individuals who opt for other treatment options (“treatment as usual”).

Read More